This study was a double-blind, randomized clinical trial. Ninety-six women undergoing elective abdominal hysterectomy were involved. The women were treated at Yas Hospital, Tehran University of Medical Sciences, from May 2019 to September 2019. This study was registered in the Clinical Trial Registry Database with IRCT No. 20190409043219N1 and approved by the Ethics and Clinical Studies Committee of Tehran University of Medical Sciences, with No. 1396, 4120.IR.TUMS.MEDICINE.REC.
The inclusion criteria were women aged between 35-65 years and ASA-PS classes I and II. Women were excluded if their surgery lasted more than 3 hours, they needed additional surgery, they experienced unusual bleeding, they needed either an intra-operative transfusion or one up to 4 hours later, and they had a history of having used a hypnotic drug within the last 72 hours.
Patients were chosen using convenience sampling. They were randomly divided into three groups of 32 patients, each using balanced block randomization. All patients received either ketamine or saline 20 min before the end of surgery. The first group received 0.25 mg/kg of ketamine, the second group received 0.5 mg/kg of ketamine, and the third group received 2 ml of normal saline.
The person who injected the drug and the patient was blind to the type of drug being administered and the patient’s group allocation. Standard anesthesia and procedures were undertaken during surgery by trained and competent staff. All equipment and medications were checked and were approved for use. Fentanyl 2 μg/kg was given to the patient first, and then 2 mg of midazolam was injected. Induction was undertaken using 2 mg/kg propofol and 0.5 mg/kg atracurium.
Once intubated, the patients remained anesthetized with a mixture of 1-1.5 MAC isoflurane in %100 oxygen, fentanyl, and atracurium were re-administered when needed. At all times, the patients were monitored in terms of non-invasive ECG, blood pressure (BP), temperature, pulse, and oxygen saturation (SpO2). The operating room temperature remained constant at all times between 23-24°C. The patient’s temperature was taken using tympanic thermometers (Welch_allyn Braun_pro 6000 Tympanic Thermometers were used). Observations were taken before injection of the induction drugs, one hour after this, before the injection of any investigational drugs, at the start of the recovery, and subsequently, 10 and 30 min following surgery. Vital signs of the patient were maintained within 20% of their baseline values. Forced air warmer was used to warm the patient if their temperature dropped below 36°C.
Twenty minutes before the end of the surgery, an anesthesiologist who was not involved in the research prepared the drugs under investigation. The drugs were coded according to a randomization method. The drugs were then injected into the patient by another anesthesiologist who did not participate in the study. At the end of the operation, the drug-induced muscle paralysis was antagonized using a mixture of neostigmine and atropine in the recovery area. A suppository of diclofenac sodium (100 mg) was administered to all patients. For patients who were still in pain, and with a visual analog scale (VAS) score higher than 3 (out of 10), 2 mg of intravenous morphine was given.
All patients were assessed to see whether they were shivering by either the recovery nurse, whilst in recovery, or by the anesthesia assistant whilst on the ward. The checks were made 0, 5, 10, 15, 20, 30, 60, 120, and 240 min following surgery. None of the staff who monitored the patients knew which type of drug had been used in this study. The degree to which the patient was shivering was assessed at five levels. Level 0: No shivering, Level 1: slight shivering (some peripheral vasoconstriction but no visible shivering), Level 2: medium level shivering (muscular activity in one muscle group only), Level 3: severe shivering (muscular activity in more than one muscle group without generalized shivering) and Level 4: whole body or generalized shivering. If the patient suffered from severe shivering (Level 3), 25 mg of pethidine was injected intravenously by a nurse in the recovery room or ward, under the authority of the anesthesiologist.
The recovery nurse in the recovery room and the anesthesia assistant on the ward recorded simultaneously the presence or absence of sedation and its severity and their pethidine requirement. They also checked whether the patients’ suffered from hallucinations, nausea, vomiting, and nystagmus status. The level of sedation was evaluated on a 5-point Likert scale. Level 0: Alert, Level 1: aroused by voice, 2: aroused by verbal command, 3: aroused by vigorous tactile stimulation, and Level 4: No response to vigorous tactile stimulation.
The clinical data were entered into SPSS software version 13. The data were analyzed using the frequency, percentage, mean, and standard deviation (descriptive statistical tests) and analytical tests (Chi-square, independent T-test, Fisher’s exact, ANOVA, and the repeated measure ANOVA). P value < 0.05 was considered statistically significant.